S. Kaestner and G. Sewell, Chemotherapy Dosing Part I: Scientific Basis for Current Practice and Use of Body Surface Area, Bibliographie [1] République Française. Décision du 5 novembre 2007 relative aux bonnes pratiques de préparation. JORF n°270 du 21 novembre 2007 page 19029 Texte n° 23. [2] Institut National du Cancer, pp.23-27, 2007.
DOI : 10.1016/j.clon.2006.10.010

D. Pinkel, The use of body surface area as a criterion of drug dosage in cancer chemotherapy, Cancer Res, vol.18, pp.853-856, 1958.

E. Freireich, E. Gehan, and D. Rall, Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man, Cancer Chemother Rep, vol.50, pp.219-244, 1966.

D. Bois, D. , D. Bois, and E. , A formula to estimate the approximate surface area if height and weight be known, Arch intern Med, vol.17, pp.863-871, 1916.

G. A. Toolkit and E. Chatelut, How to implement dose-banding of chemotherapy. Cancer Network Pharmacists Forum http://www.bopawebsite.org/contentimages/publications/Toolkit_Ver_3 Pourquoi individualiser les doses de médicaments anticancéreux : de la surface corporelle à la physiologie, 0_FINAL.pdf. Bull Cancer, vol.95, issue.10, pp.895-901, 2008.

L. Grochow, C. Baraldi, D. Noe, S. Baker, J. Verweij et al., Is dose normalization to weight or body surface area useful in adults ? Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001 Rationalisation of chemotherapy services in the University Hospital Birmingham National Health Science Trust, J Natl Cancer Inst. J Natl Cancer Inst. J Oncol Pharm Pract, vol.8210114, issue.94241, pp.323-325, 1990.

R. Plumridge and G. Sewell, Dose-banding of cytotoxic drugs : a new concept in cancer chemotherapy, Am J Health-Syst Pharm, vol.58, pp.1760-1764, 2001.

I. Roland, C. Pirotton, and M. Deprez, Aspects théoriques (Partie I) Pharmakon Guidelines for the dose-banding of cancer chemotherapy. North of England Cancer Network Can logarithmic dose-banding simplify chemotherapy preparation and administration ? Packaging and Safety Symposium Report, Clin Pharm, vol.41143, issue.2, pp.3-13116, 2009.

J. Vigneron, S. Garnier, and A. Delfour, http://www.infostab.fr/upload/files/7400d580cd21f2014ff102526803fcf36df742c0/Poster_sta ndardisation_SFPO_2013_OK.pdf?PHPSESSID=g035dqn445uncqq2ti84mfeh6 [Consulté le 18 mars]. [18] International Society of Oncology Pharmacy Practitioners. Standards of practice : safe handling of cytotoxics A national survey investigating UK prescribers' opinions on chemotherapy dosing and dose-banding Dose rounding of chemotherapy in colorectal cancer : an analysis of clinician attitudes and the potential impact on treatment costs, J Oncol Pharm Pract. J Clin Oncol Asia Pac J Clin Oncol, vol.21206, pp.1-81320, 2007.

P. Jenkins, R. Wallis, W. Loss, H. Gelderblom, and A. Sparreboom, Dose-rounding of adjuvant chemotherapy for breast cancer: an audit of toxicity Inter-and intrapatient variability in oral topotecan pharmacokinetics : implications for body-surface area dosage regimens, J Oncol Pharm Pract. Clin Cancer Res, vol.16236, issue.47, pp.251-2552685, 2000.

M. Rudek, R. Connolly, and J. Hoskins, Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer, Breast Cancer Research and Treatment, vol.783, issue.1, pp.135-143, 2001.
DOI : 10.1016/S1570-0232(02)00674-8

P. Memorandum, N. Field, K. Kosmider, S. Jefford, and M. , Chemotherapy dosing strategies in the obese, elderly, and thin patient : result of a nationwide survey, Consulté le 10 août 2014] [27], pp.108-113, 2008.

J. Griggs, P. Mangu, and H. Anderson, Appropriate chemotherapy dosing for obese adult patients with cancer American Society of Clinical Oncology Clinical Practice Guideline Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from Cancer and Leukemia Group B Study 8541 Flat-fixed dosing versus Body Surface Areabased dosing of anticancer drugs in adults : does it make a difference ? The Oncol, J Clin Oncol. J Clin Oncol, vol.30143012, issue.13, pp.1553-15613000, 1996.

R. Danesi, D. Braud, F. Fogli, and S. , Pharmacogenetic determinants of anti-cancer drug activity and toxicity, Trends in Pharmacological Sciences, vol.22, issue.8, pp.420-426, 2001.
DOI : 10.1016/S0165-6147(00)01742-9

J. Beumer, E. Chu, and S. Salomone, Body-surface area-based chemotherapy dosing : appropriate in the 21st century ? [33] So J. Improving the lives of patients with cancer, J Clin Oncol. Pharm Manage, vol.3018, pp.2896-389727, 2002.

S. Kaestner and G. Sewell, Chemotherapy Dosing Part II: Alternative Approaches and Future Prospects, Clinical Oncology, vol.19, issue.2, pp.99-107, 2007.
DOI : 10.1016/j.clon.2006.10.003

G. Sewell, M. White-koning, and R. Mathijssen, The clinical impact of dose-banding. Congrès du GERPAC Dose-banding as an alternative to body surface area-based dosing of chemotherapeutic agents, Br J Cancer, vol.107, pp.1100-1106, 2006.

S. Kaestner, G. Sewell, S. Kaestner, G. Sewell, S. Kaestner et al., Pharmacoeconomic aspects of dose-banding A sequential temperature cycling study for the investigation of carboplatin infusion stability to facilitate " dose-banding " Dose-banding of carboplatin : rationale and proposed banding scheme, Hospital Pharmacy Europe. J Oncol Pharm Pract. J Oncol Pharm Pract, vol.2638133913, pp.119-126109, 2006.

F. Maclean, J. Macintyre, and J. Mcdade, Dose-banding of chemotherapy in the Edinburgh Cancer Centre, Pharm J, vol.270, pp.691-693, 2003.

H. Hirte, S. Kagoma, and L. Zhong, Dose-banding of chemotherapy doses at the Juravinski Cancer Centre [42] Leth-Miller D. Dose-banding of gemcitabine Interest of dose-banding in the preparation of 5-FU infusors in ambulatory care Preliminary study to implement dose-banding in a teaching hospital, PRI52.pdf, pp.6099127-6099172, 2006.

G. Loison, G. Phelps, and R. Tortora, Mémoire de DES de Pharmacie Hospitalière Angers : Université d'Angers. 107p. [47] Infostab, Mise en place des doses standards de chimiothérapie au Centre Hospitalier du Mans Response rate and measurement differences in mixed-mode surveys using mail, telephone, interactive voice response (IVR) and the Internet

W. Health-organization-vigneron, J. Astier, A. Trittler, and R. , Guidelines for stability testing of pharmaceutical products containing well established drug substances in conventional dosage forms. WHO Tech Rep Series SFPO and ESOP recommendations for the practical stability of anticancer drugs : an update, Ann Pharm Fr, vol.86351, issue.71, pp.376-389, 1996.

Y. Zhang and L. Trissel, Physical Instability of Frozen Pemetrexed Solutions in PVC Bags, Annals of Pharmacotherapy, vol.50, issue.7-8
DOI : 10.1345/aph.1G161

S. Roy and M. Desroches, Stability of oxaliplatin solution, Ann Pharmacother. Ann Pharmacother, vol.40, issue.432, pp.1289-1292, 2006.

L. Trissel, Q. Xu, L. Pham, S. Roberts, and G. Sewell, Physical and chemical stability of hydromorphone hydrochloride 1.5 and 80 mg/mL packaged in plastic syringes Stability and compatibility of 5-fluorouracil infusions in the Braun Easypump®, ) : 109-112. [56] Rochard E, Bouquet G, Chapelle S et al. Stability of fluorouracil and cytarabine in ethylvinylacetate containers, pp.74-76, 1989.

K. Morand, M. Paul, and A. Lahlou, Stabilité de solutions diluées de bevacizumab en fonction de la température Congrès de la SFPO A sequential temperature cycling study for the investigation of carboplatin infusion stability to facilitate " dose-banding " [59] Fresenius Kabi. Dossier Technique Freeflex, www.stabilis.org/Bibliographie.php?IdBiblio=2882 [Consulté le 17 juin 2014]. [58], pp.119-126, 2001.

E. Pharma and . Stability-of-alexan, Ebewe" infusion solutions http://www.stabilis.org [Consulté le 17 juin 2014] [62] Ebewe Pharma. Stability of doxorubicin " Ebewe " infusion solutions, p.76, 2007.

Y. Zhang and L. Trissel, Physical and chemical stability of gemcitabine hydrochloride solutions, Laboratoire Servier. Muphoran® Résumé des caractéristiques du produit, pp.509-513, 1999.

J. Thiesen, I. Krämer, S. Cisternino, and A. Roy, Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags, Journal of Oncology Pharmacy Practice, vol.1, issue.3, pp.115-121, 2000.
DOI : 10.1191/107815599678847168

X. Liu, G. Sewell, . Poster, C. Congrès-de-l-'esop, M. Cohen et al., [69] 5-Fluorouracile Résumé des caractéristiques du produit Bevacizumab (Avastin®) Résumé des caractéristiques du produit FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme. The Oncol Association des Neuro-Oncologues d'Expression Française. Référentiel de l'ANOCEF pour les gliomes de l'adulte Anticancéreux : Utilisation pratique 6 ème édition, www.theriaque.org [Consulté le 30 juillet 2014www.theriaque.org [Consulté le 30 juillet 2014] [74] Centre National Hospitalier d'Information sur le Médicament, pp.1131-1138, 1999.

G. Michel, C. Menard, and P. Faure, Dose-banding of chemotherapy agents and its implications for hematology-oncology practice. Poster, Congrès de l'ADKA http://www.adka.de/solva_docs/ADKAPosterHamburg2014_reinhardt.pdf [86] Larousse ? Dictionnaire en ligne Maîtrise Universitaire d'Etudes Avancées ? Séminaire « La préparation des médicaments parentéraux à l'hôpital » Pompes pour la préparation aseptique de seringues de chimiothérapies anticancéreuses, p.78, 2011.

A. Hurgon, A. Chassin, and C. Giard, http://www.apoteca.it [Consulté le 17 août 2014] [94] Health Robotics Préparation centralisée de chimiothérapies : comparaison entre l'acquisition d, Consulté le 17 août 2014] [93] Loccioni Humancare, 2007.

S. Walker, D. Milliken, and S. Law, Stability of Bortezomib Reconstituted with 0.9% Sodium Chloride at 4°C and Room Temperature (23°C) Can, J Hosp Pharm, vol.61, issue.1, pp.14-20, 2008.